F Verheugt
Overview
Explore the profile of F Verheugt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
261
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Vugt S, Aarts G, Lamfers E, Vries L, Kramers C, de Boer M, et al.
Eur Cardiol
. 2020 Jul;
15:e46.
PMID: 32612706
No abstract available.
2.
Cohen A, Lip G, De Caterina R, Heidbuchel H, Zamorano J, Agnelli G, et al.
Vascul Pharmacol
. 2018 Apr;
106:9-21.
PMID: 29656119
Atrial fibrillation (AF) and venous thromboembolism (VTE) are cardiovascular conditions significant in contemporary practice. In both, the use of anticoagulation with vitamin K antagonists (VKAs) has been traditionally used to...
3.
Berndt N, de Vries H, Lechner L, Van Acker F, Froelicher E, Verheugt F, et al.
Neth Heart J
. 2016 Oct;
25(1):24-32.
PMID: 27752966
Background: Without assistance, smokers being admitted to the hospital for coronary heart disease often return to regular smoking within a year. Objective: This study assessed the 12-month effectiveness of a ...
4.
Korte W, Cattaneo M, Chassot P, Eichinger S, von Heymann C, Hofmann N, et al.
Thromb Haemost
. 2011 Mar;
105(5):743-9.
PMID: 21437351
An increasing number of patients suffering from cardiovascular disease, especially coronary artery disease (CAD), are treated with aspirin and/or clopidogrel for the prevention of major adverse events. Unfortunately, there are...
5.
Wallentin L, Goldstein P, Armstrong P, Granger C, Adgey A, Arntz H, et al.
Circulation
. 2003 Jul;
108(2):135-42.
PMID: 12847070
Background: The combination of a single-bolus fibrinolytic and a low-molecular-weight heparin may facilitate prehospital reperfusion and further improve clinical outcome in patients with ST-elevation myocardial infarction. Methods And Results: In...
6.
Van de Werf F, Adgey J, Ardissino D, Armstrong P, Aylward P, Barbash G, et al.
Lancet
. 1999 Sep;
354(9180):716-22.
PMID: 10475182
Background: Bolus fibrinolytic therapy facilitates early efficient institution of reperfusion therapy. Tenecteplase is a genetically engineered variant of alteplase with slower plasma clearance, better fibrin specificity, and high resistance to...
7.
8.
Verheugt F
Rev Port Cardiol
. 1999 Feb;
17(12):959-65.
PMID: 9973856
The optimal thrombolytic regimen is front-loaded alteplase with vigorous heparinization: the reperfusion treatment that leads to the lowest 30 day mortality. The role of heparin alone or in combination with...